![]() |
|
|
Vol. 18, Issue 11, 4659-4668, November 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



,
*Laboratory of Endothelial Cell Biology, Institut de recherches cliniques de Montréal (IRCM), Montréal, QC, H2W 1R7, Canada; Departments of
Pharmacology and
Medicine, Université de Montréal, Montréal, QC, H3C 3J7, Canada; and
Le Centre de Recherche en Cancérologie de l'Université Laval, Québec, QC, G1R 2J6, Canada
Submitted May 18, 2007;
Revised August 29, 2007;
Accepted August 31, 2007
Monitoring Editor: Martin A. Schwartz
Nitric oxide (NO) release from endothelial cells, via endothelial NO synthase (eNOS) activation, is central to the proangiogenic actions of vascular endothelial growth factor (VEGF). VEGF signaling to eNOS is principally mediated by an Akt-dependent phosphorylation of eNOS and by increased association of eNOS to the molecular chaperone, heat-shock protein 90 kDa (Hsp90). Herein, we report that VEGFR-2 activation induces tyrosine phosphorylation of VEGF receptor 2 (VEGFR-2)-associated Hsp90
. Tyrosine phosphorylation of Hsp90
in response to VEGF is dependent on internalization of the VEGFR-2 and on Src kinase activation. Furthermore, we demonstrate that c-Src directly phosphorylates Hsp90 on tyrosine 300 residue and that this event is essential for VEGF-stimulated eNOS association to Hsp90 and thus NO release from endothelial cells. Our work identifies Y300 phosphorylation of Hsp90 as a novel regulated posttranslational modification of the chaperone and demonstrates its importance in the proangiogenic actions of VEGF, namely by regulating NO release from endothelial cells.
The online version of this article contains supplemental material at MBC Online (http://www.molbiolcell.org).
Address correspondence to: Jean-Philippe Gratton (jean-philippe.gratton{at}ircm.qc.ca)
Abbreviations used: BAECs, bovine aortic endothelial cells; eNOS, endothelial nitric oxide synthase; GA, geldanamycin; HA, hemagglutinin; Hsp90, heat-shock protein 90 kDa; HUVECs, human umbilical vein endothelial cells; NO, nitric oxide; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
This article has been cited by other articles:
![]() |
J. DaSilva, D. Gioeli, M. J. Weber, and S. J. Parsons The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor Cancer Res., September 15, 2009; 69(18): 7402 - 7411. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Su, J.-Y. Tsai, Y. R. Kou, A.-N. Chiang, S.-H. Hsiao, Y.-L. Wu, H.-H. Hou, C.-C. Pan, S.-K. Shyue, and T.-S. Lee Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling Cardiovasc Res, June 1, 2009; 82(3): 468 - 475. [Abstract] [Full Text] [PDF] |
||||